

Epithelial Sodium Channel (ENaC)

Hongbao Ma * **, Yan Yang **

Bioengineering Department, Zhengzhou University, Zhengzhou, Henan 450001, China,; ma8080@gmail.com;
01186-137-8342-5354

** Brookdale University Hospital and Medical Center, New York 11212, USA, youngjenny2008@yahoo.com;
1-347-321-7172

Abstract: The epithelial sodium channel (ENaC) is a cell membrane-bound ion-channel that is permeable for Na⁺, Li⁺ and H⁺, and it is a major regulator of salt and water reabsorption in a number of epithelial tissues. Abnormalities in ENaC function have been directly linked to several human disease states including Liddle's syndrome, psuedohypoaldosteronism, and cystic fibrosis and may be implicated in states as diverse as salt-sensitive hypertension, nephrosis, and pulmonary edema. ENaC activity in epithelial cells is highly regulated both by open probability and number of channels. In animal kidney, ENaC plays a crucial role in controlling sodium reabsorption to keep the normal blood pressure. The expression of ENaC is abnormally regulated by dietary sodium in salt-sensitively hypertensive rats, and that this abnormal expression would be one of the factors causing salt-sensitive hypertension. [Journal of American Science 2009; 5(6):62-69]. (ISSN: 1545-1003).

Keywords: epithelial sodium channel (ENaC); Aldosterone: pioglitazone; Thiazolidinedione; serum- and glucocorticoid-inducible kinase (SGK); angiotensin-converting enzyme (ACE); inhibitor; hypertension; chronic heart failure. Renal; kidney

1. Introduction

The epithelial sodium channel (ENaC), also named sodium channel non-neuronal 1 (SCNN1) or amiloride sensitive sodium channel (ASSC), is a cell membrane-bound ion-channel that is permeable for Na⁺, Li⁺ and H⁺, and it is a major regulator of salt and water reabsorption in a number of epithelial tissues. Abnormalities in ENaC function have been directly linked to several human disease states including Liddle's syndrome, psuedohypoaldosteronism, and cystic fibrosis and may be implicated in states as diverse as salt-sensitive hypertension, nephrosis, and pulmonary edema. ENaC activity in epithelial cells is highly regulated both by open probability and number of channels. Open probability is regulated by a number of factors, including proteolytic processing, while ENaC number is regulated by cellular trafficking. It is important to understand apical membrane delivery, cell surface stability, endocytosis, retrieval, recycling of ENaC, the molecular partners that have so far been shown to participate in these processes, and sites and mechanisms of hormonal regulation of trafficking by aldosterone, vasopressin, and insulin (Butterworth et al., 2009).

ENaC activity is limiting for sodium reabsorption in the distal nephron. Humans regulate blood pressure by fine-tuning sodium balance through control of ENaC. ENaC dysfunction causes some hypertensive and renal salt wasting diseases. According to the recent report, ENaC is sensitive to phosphatidylinositol 4,5-bisphosphate (PIP₂), the

target of phospholipase C-mediated metabolism, and phosphatidylinositol 3,4,5-trisphosphate (PIP₃), the product of phosphatidylinositide 3-OH kinase (PI3-K). PIP₂ is permissive for ENaC gating possibly interacting directly with the channel. Activation of distal nephron P₂Y receptors tempers ENaC activity by promoting PIP₂ metabolism. This is important because gene deletion of P₂Y₂ receptors causes hypertension associated with hyperactive ENaC. Aldosterone, the final hormone in a negative-feedback cascade activated by decreases in blood pressure, increases ENaC activity. PIP₃ sits at a critical bifurcation in the aldosterone-signaling cascade, increasing ENaC open probability and number. PIP₃-effectors mediate increases in ENaC number by suppressing channel retrieval. PIP₃ binds ENaC, at a site distinct from that important to PIP₂ regulation, to modulate directly open probability (Pochynyuk et al., 2008).

The renal epithelial sodium channel (ENaC) is of fundamental importance in the control of sodium reabsorption through the distal nephron. ENaC is an important component in the overall control of sodium balance, blood volume and thereby of blood pressure. This is clearly demonstrated by rare genetic disorders of sodium channel activity (Liddle's Syndrome and Pseudohypoaldosteronism type 1 associated with contrasting effects on blood pressure). Subtle dysregulation of ENaC however may also be important in essential hypertension - a common condition and a major cause of cardiovascular morbidity and mortality.

The epithelial sodium channel is formed from three partly homologous subunits. In this review we deal firstly with current views of structural and functional features of the renal epithelial sodium channel with particular emphasis on mechanisms and processes involved in the control of sodium channel activity at the biochemical and cellular levels. We then focus on genetic aspects with reference to the significance of genetic variation in the sodium channel genes in relation to blood pressure. In particular, we review recent investigations on the potential clinical significance of mutations within the genes encoding ENaC subunits in individuals with high blood pressure. Lastly, we also examine the potential value of pharmacological targeting of the renal epithelial sodium channel with the sodium channel inhibitor amiloride for the treatment of hypertension (Sagnella and Swift, 2006).

Lithium is used commonly to treat bipolar mood disorders. In addition to its primary therapeutic effects in the central nervous system lithium has a number of side effects in the kidney. The side effects include nephrogenic diabetes insipidus with polyuria, mild sodium wasting, and changes in acid/base balance. These functional changes are associated with marked structural changes in collecting duct cell composition and morphology, likely contributing to the functional changes (Nielsen et al., 2008).

The apical membrane of many tight epithelia contains sodium channels that are primarily characterised by their high affinity to the diuretic blocker amiloride. These channels adjust the sodium reabsorption for the maintenance of body salt and water homeostasis. In vertebrate animals, ENaC is involved in the reabsorption of sodium in kidney, colon, lung and sweat glands; they also play a role in taste perception.

Amiloride was originally described in 1967 as a potassium-sparing diuretic, the mechanism of action of which is to block the ENaC within the distal tubule of the kidney. In addition, higher doses of amiloride were found to be capable of inhibiting the Na(+)/H(+) exchangers (NHE) and the Na(+)/Ca(2+) exchangers. In time, several amiloride analogs have been synthesized to have a marked increase in their specificity to inhibit the ENaC, the NHE or the Na(+)/Ca(2+) exchangers. Although the NHE inhibitors have received the most recent attention, large-scale clinical trials using NHE inhibitors in ischemic cardiac states have shown them to be either ineffective or associated with an unacceptable risk profile. Aldosterone excess in animal models is known to cause cardiovascular injury, and blockade of mineralocorticoid receptors in human beings with heart disease improves outcomes. However, the exact mechanisms of aldosterone injury in animal models of

hypertensive disease and protection with mineralocorticoid receptor antagonists in human trials of heart failure remain unknown. These effects are unexplained by changes in BP, potassium, or sodium balance. An additional possibility is that aldosterone action and mineralocorticoid receptor blockade is conferred by alterations in ENaC activity. Emerging experimental evidence suggests the possibility that systemic or central ENaC inhibition or both may be an alternative to the treatment of hypertension and cardiovascular disease states. Clinical trials to evaluate further the potential beneficial cardiovascular effects of ENaC blockade are needed. This article reviews the case for ENaC inhibition as a potential target for cardiovascular and renal protection in human beings (Teiwes and Toto, 2007).

The ENaC has a central role in sodium transport across membranes. It is expressed on the apical cell surface of renal tubular epithelia and also on other aldosterone-responsive epithelial cells. In the kidney, ENaC contributes to the regulation of blood pressure via changes in sodium balance and blood volume. Rare monogenetic disorders associated with hypertension have been described, such as Liddle syndrome, which gives rise to increased sodium reabsorption in the kidney via increased ENaC activity. There are many other variants in the genes encoding ENaC subunits, some of which occur with sufficient frequency as to be termed polymorphic variants. The Thr594Met polymorphism of the ENaC beta-subunit gene SCNN1B occurs exclusively in Black individuals, with a frequency of 6-8% in those with hypertension. It increases cAMP mediated ENaC sodium current in affected B lymphocytes, and has been associated with hypertension in a Black South London population. There is preliminary evidence that amiloride is effective as monotherapy in hypertensive individuals with the Thr594Met polymorphism and in patients with resistant hypertension, who have evidence of increased amiloride-sensitive sodium channel activity. If these preliminary studies are corroborated in larger studies, then amiloride may provide an important new strategy for blood pressure control in selected individuals (Swift and MacGregor, 2004).

The epithelial sodium channel (ENaC) is a membrane protein made of three different but homologous subunits (a, b, and g) present in the apical membrane of epithelial cells of, for example, the distal nephron. This channel is responsible for salt reabsorption in the kidney and can cause human diseases by increasing channel function in Liddle's syndrome, a form of hereditary hypertension, or by decreasing channel function in pseudohypoaldosteronism type I, a salt-wasting disease in infancy. This review briefly discusses recent

advances in understanding the implication of ENaC in Liddle's syndrome and in pseudohypoaldosteronism type I, both caused by mutations in the SCNN1 (ENaC) genes. Furthermore, it is still an open question to which extent SCNN1 genes coding for ENaC might be implicated in essential hypertension. The development of Scnn1 genetically engineered mouse models will provide the opportunity to test the effect of environmental factors, like salt intake, on the development of this kind of salt-sensitive hypertension (Hummler, 2003).

The epithelial sodium channel (ENaC) is of fundamental importance in the control of sodium fluxes in epithelial cells. Modulation of sodium reabsorption through the distal nephron ENaC is an important component in the overall control of sodium balance, blood volume and thereby of blood pressure. This is clearly demonstrated by rare genetic disorders of sodium-channel activity (Liddle's syndrome and pseudohypoaldosteronism type 1), associated with contrasting effects on blood pressure. The mineralocorticoid aldosterone is a well-established modulator of sodium-channel activity. Considerable insight has now been gained into the intracellular signalling pathways linking aldosterone-mediated changes in gene transcription with changes in ion transport. Activating pathways include aldosterone-induced proteins and especially the serum- and glucocorticoid-inducible kinase (SGK) and the small G-protein, K-Ras 2A. Targeting of the ENaC for endocytosis and degradation is now emerging as a major mechanism for the down-regulation of channel activity. Several proteins acting in concert are an intrinsic part of this process but Nedd4 (neural precursor cell expressed developmentally down-regulated 4) is of central importance. Other mechanisms known to interact with ENaC and affect sodium transport include channel-activating protease 1 (CAP-1), a membrane-anchored protein, and the cystic fibrosis transmembrane regulator. The implications of research on accessory factors controlling ENaC activity are wide-ranging. Understanding cellular mechanisms controlling ENaC activity may provide a more detailed insight not only of ion-channel abnormalities in cystic fibrosis but also of the link between abnormal renal sodium transport and essential hypertension (Gormley et al., 2003).

The activity of epithelial sodium channels (ENaC) is increased by phosphatidylinositides, especially phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P₃). Stimulation of phospholipase C by either adenosine triphosphate (ATP)-activation of

purinergic P₂Y receptors or epidermal growth factor (EGF)-activation of EGF receptors reduces membrane PI(4,5)P₂, and consequently decreases ENaC activity. Since ATP and EGF may be trapped in cysts formed by the distal tubule, it is possible that ENaC inhibition induced by ATP and EGF facilitates cyst formation in polycystic kidney diseases (PKD). However, some results suggest that ENaC activity is increased in PKD. In contrast to P₂Y and EGF receptors, stimulation of insulin-like growth factor-1 (IGF-1) receptor by aldosterone or insulin produces PI(3,4,5)P₃, and consequently increases ENaC activity. The acute effect of aldosterone on ENaC activity through PI(3,4,5)P₃ possibly accounts for the initial feedback for blood volume recovery after hypovolemic hypotension. PI(4,5)P₂ and PI(3,4,5)P₃, respectively, interacts with the N terminus of beta-ENaC and the C terminus of gamma-ENaC. However, whether ENaC selectively binds to PI(4,5)P₂ and PI(3,4,5)P₃ over other anionic phospholipids remains unclear (Ma et al., 2007).

The appropriate regulation of sodium (Na⁺) absorption in the aldosterone-sensitive distal nephron (ASDN) is essential to precisely match urinary Na⁺ excretion to dietary Na⁺ intake whilst taking extra-renal Na⁺ losses into account. There is increasing evidence that Na⁺ transport in the connecting tubule (CNT) is of particular importance for the maintenance of body Na⁺ balance and for the long-term control of extra-cellular fluid volume and arterial blood pressure. Na⁺ transport in the CNT critically depends on the activity and abundance of the amiloride-sensitive epithelial sodium channel (ENaC) in the luminal membrane of the CNT cells. As a rate-limiting step for transepithelial Na⁺ transport, ENaC is the main target of hormones (e.g. aldosterone, angiotensin II, vasopressin and insulin/insulin-like growth factor 1) to adjust transepithelial Na⁺ transport in this tubular segment (Löffing and Korbmayer, 2009).

2. Structure

ENaC consists of 4 subunits that are named α -, β -, γ -, δ -ENaC. Each of the subunits consists of two transmembrane helices and an extracellular loop. The amino- and carboxy-termini of all polypeptides are located in the cytosol. One subunit consists of about 510 to 920 amino acid residues, which is made of an intracellular N-terminus region followed by a transmembrane domain, a large extracellular loop, a second transmembrane segment and a C-terminal intracellular tail.

Human ENaC-alpha subunit sequence (669 amino acid):

```

1 megnkleeqd sspqstpgl mkgnkreeqg lgpepaapqg ptaeeelialie fhrsyrlelfe
61 ffcnnttthg airlvcsqhn rmktafawvl wlctfgmmyw qfgllfgeyf sypvslninl
121 nsdklvfpav tiactlnpyry peikeeleel driteqtlfd lykyssfttl vagsrrrdl
181 rgtlphplqr lrvpppphga rrarsvassl rdnnpqvdwk dwkigfqlcn qnksdcfyqt
241 yssgvдавre wyrfhyinil srlpetlpsl eedtlgnfif acrfnqvscn qanyshfhhp
301 mygncytfnd knnsnlwmss mppginnlsl mlraeqndfi pllstvtgar vmvhgqdepa
361 fmdgggfnlr pgvetsismr ketldrlggd ygdctkngsd vpvenlypsk ytqqvcihsc
421 fquesmikecg cayifypprq nveycdyrkh sswgycyykl qvdfssdhlg cftkcrkpcs
481 vtsyqlsagy srwpsvtsqe wvfqmlsrqn nytvnnkrng vakniffke lnyktnsesp
541 svtmvtllsn lgsqwslwfg ssvlsvvema elvfdllvim flmlrrfrs rywspgrggr
601 gagevastla sspshfcph pmslslsqpg papsaltap ppayatlgpr pspggsagas
661 sstcplggp

```

Reference:

AUTHORS Chow, Y.H., Wang, Y., Plumb, J., O'Brodovich, H. and Hu, J.
 TITLE Hormonal regulation and genomic organization of the human
 amiloride-sensitive epithelial sodium channel alpha subunit gene
 JOURNAL *Pediatr. Res.* 46 (2), 208-214 (1999)

Human ENaC-beta subunit sequence (640 amino acid):

```

1 mhvkkyllkg lhrlqkpggy tykellvwyd dntnthgpkrr iicegpkkka mwfltl1lfa
61 alvcwqwgif irtylswevs vslsvqfktm dfpavticna spfkyskikh lkldldelme
121 avlerilape lshanatrl nfsiwnhtpl vlidernphh pmvldlfgdn hngltssas
181 ekicnahgck mamrlcslnr tqctfrnfts atqaltewyi lqatnifaqv pqqelvemsy
241 pgegmilacl fgaepcnyrn ftsifyphyg ncyifnwgmt ekalpsanpg tefglklild
301 iggedyvpfl astagvrml heqrsypfir degiypmsgt etsigvlvdk lqrmgepypsp
361 ctvngsevvp qnfysdyntt ysiqaclrsc fgdhmirncn cghylyplpr gekycnrdf
421 pdwahcysdl qmsvaqretc igmckescnd tqykmisma dwpseasedw ifhvlsqerd
481 qstnitlsrk givklriffq efnrytiees aannivwlls nlggqfgfwg ggsvlclief
541 geiiddfwi tiiklvalak slrqrraqs yagppptvae lveahntfgf qpdtaprspn
601 gtypsequal pipgtpppny dslrlqpldv iesdsegdai

```

Reference:

AUTHORS McDonald, F.J., Price, M.P., Snyder, P.M. and Welsh, M.J.
 TITLE Cloning and expression of the beta- and gamma-subunits of the human
 epithelial sodium channel
 JOURNAL *Am. J. Physiol.* 268 (5 PT 1), C1157-C1163 (1995)

Human ENaC-gama subunit sequence (649 amino acid):

```

1 mapgekikak ikknlpvtgp qaptikelmr wyclntnthg crrivvsrgr lrrllwigft
61 ltavalilwq callvfsfyt vsvsikvhfr kldfpavtic ninpykystv rhlladleqe
121 trealkslyg fpearkrrea eswnsvsegk qprfshripl lifdqdekkg ardfftgwkr
181 kvgsiika snvmhieskq vvgfqlcsnd tsdcatyfts sginaiqewy klhymnimaq
241 vplekinms ysaellvtc ffdgvsodar nftlfhhpmh gncytfnre netilstsmg
301 gseyglqvil yineeynpf lvsstgakvi ihrqdeyfpv edvgteieta mvtsigmhlt
361 esfklsepys qctedgsdvp irniynaays lqiclhscfk tkmvekcgca qysqplppaa
421 nycnyqghpn wmcyyqqlhr afvqeelgcq svckeacsfk ewtltslaq wpsvsvsekwl
481 lpvltwdqgr qvnkklntkd lpkllifykd lnqrsimesp ansiemllsn fggqlglwms
541 csvvcvieii evffidffsi iarrwqkak ewwawkqapp cpeaprspqg qdnpaldidd
601 dlptfnsalh lpslgtqvp gtpppkyntl rlerafsnql tdtqmdel

```

Reference:

AUTHORS McDonald, F.J., Price, M.P., Snyder, P.M. and Welsh, M.J.
 TITLE Cloning and expression of the beta- and gamma-subunits of the human
 epithelial sodium channel
 JOURNAL *Am. J. Physiol.* 268 (5 PT 1), C1157-C1163 (1995)

Human ENaC-delta subunit sequence (704 amino acid):

```

1 mafslrtspv aasfqsrqe arg sillqsc qlppqwlste awtgewkqph ggaltsrspg
61 pvapqrphl kgwqhrptqh naackqgqaa aqtpprpgpp sapppppkge hqeglvelpa
121 sfrelltffc tnatihgair lvcsrgnrk tswgllslg alvalcwqlg llferhwhrp
181 vlmavsvhse rkllplvtlc dgnprprspv lrhlleldef arenidslyn vnlsgkraal
241 satvprhepp fhldreirlq rlshgsrsvr vgfrcnstg gdcfyrgyts gvaavqdwyh
301 fhyvdilall paawedshgs qdghfvlses ydgldeqarq frtfhhptyf scytdvgwvt
361 aqrpgithgv glvlrveqpp hlpllstlag irvmvghrnh tpfllghhsfs vrpgteatis
421 iredevhrig spyghctagg egvevellhn tsytrqaclv scfqqlmvvet cscgyylhpl
481 pagaeycssa rhpawghcfy rlyqdlethr lpctsrprp cresafklst gtsrwsaks
541 agwtlatlge qglphqshrq rsslakiniv yqelnysrve eapvysvpql lsamgslcsl
601 wfgasvslsl ellellldas altlvlgrr lrrawfswpr aspasgassi kpeasqmppp
661 agttsddpep sgphlprvml pgvlagvsae eswagpape tldt

```

Reference:

AUTHORS Yamamura,H., Ugawa,S., Ueda,T., Nagao,M., Joh,T. and Shimada,S.
 TITLE Epithelial Na⁺ channel delta subunit is an acid sensor in the human oesophagus
 JOURNAL Eur. J. Pharmacol. 600 (1-3), 32-36 (2008)

3. Location and function

ENaC is located in the apical membrane of polarized epithelial cells particularly in the kidney, lung and colon. It is involved in the transepithelial Na⁺ transport that accomplishes with Na⁺/K⁺-ATPase. ENaC plays a major role in the Na⁺ and K⁺ homeostasis of blood, epithelia and extraepithelial fluids by resorption of Na⁺. The activity of ENaC in colon and kidney is modulated by the mineralcorticoid aldosterone. It can be blocked by either triamterene or amiloride, which are used medically to serve as diuretics.

ENaC exists in taste receptor cells also, where it is involved in salt taste perception. In rodents the entire salt taste is mediated by ENaC, whereas in human about 20% taste comes from the ENaC.

Units β and γ are associated with Liddle's syndrome. Amiloride and triamterene are potassium-sparing diuretics which act as epithelial sodium channel blockers.

4. Interaction with Cystic fibrosis transmembrane conductance regulator

ENaC interaction with **Cystic fibrosis transmembrane conductance regulator (CFTR)** is arguably of the most important pathophysiological relevance in cystic fibrosis. CFTR is a membrane bound protein responsible for chloride transport. In a normal sweat gland, CFTR and ENaC are responsible for salt reabsorption from the sweat glands. CFTR has an *stimulatory* effect on ENaC in the sweat glands only. In cystic fibrosis, the CFTR channel does not work, so ENaC is also inhibited. Hence, the sweat of the patient can physically be tasted to be salty. This was a common technique to help diagnose the disease

prior to modern methods. In the airway, CFTR has an *inhibitory* effect on ENaC everywhere *except* the sweat glands. Normally, chloride is secreted into the airway mucous and sodium is absorbed. However, in cystic fibrosis, chloride is not secreted and ENaC is not inhibited. Hence, sodium absorption markedly increases. Lower salt in the mucous results in very thick and viscous mucous, containing far less water than normal (recall that salt has a water retaining property via osmosis and a depletion will result in less water retained). This causes many problems from increased difficulty breathing to a predisposition to catching respiratory tract diseases.

5. Families

ENaC includes 4 subfamilies: α (alpha), β (beta), γ (gamma) and δ (delta). The proteins exhibit the same apparent topology, each with two transmembrane spanning segments, separated by an extracellular loop. The extracellular domains are highly conserved and contain numerous cysteine residues, with flanking C-terminal amphipathic transmembrane regions which pays roles in the formation of the hydrophilic pores of the oligomeric channel protein complexes.

Vertebrate ENaC proteins are similar to degenerins of *Caenorhabditis elegans* deg-1, del-1, mec-4, mec-10 and unc-8. These proteins can be mutated to cause neuronal degradation, and are also thought to form sodium channels.

6. Genes

The exon–intron architecture of the three genes encoding the three subunits of ENaC have remained highly conserved despite the divergence of their sequences.

Human ENaC-alpha subunit gene 2010 bp, mRNA:

```

1 atggagggga acaagctgga ggagcaggac tctagccctc cacagtccac tccagggctc
61 atgaagggga acaagcgtga ggagcagggg ctgggccccg aacctgcggc gccccagcag
121 cccacggcgg aggaggaggc cctgatcgag ttccaccgct cctaccgaga gctcttcgag
181 ttctttctgca acaacaccac catccacggc gccatccgcc tgggtgtgctc ccagcacaac
241 cgcataaaga cgccttctg ggcagtctg tggctctgca ccttggcat gatgtactgg
301 caattcggcc tgcctttctg agagtacttc agctaccccg tcagcctcaa catcaacctc
361 aactcggaca agctcgtctt ccccgagctg accatctgca ccctcaatcc ctacaggtac
421 ccgaaaatta aagaggagct ggaggagctg gaccgcatca cagagcagac gctctttgac
481 ctgtacaaat acagctcctt caccactctc gtggcgggct cccgcagcgc tcgcgacctg
541 cgggggactc tgcgcacccc cttgcagcgc ctgaggggtcc cgccccgcgc tcacggggcc
601 cgtcagagcc gtacgctggc ctccagcttg cgggacaaca acccccaggt ggactggaag
661 gactggaaga tcggcttcca gctgtgcaac cagaacaaat cggactgctt ctaccagaca
721 tactcatcag ggtggatgc ggtgagggag tggtaaccgt tccactacat caacatcctg
781 tcgaggctgc cagagactgc gccatccctg gaggaggaca cgctgggcaa cttcatcttc
841 gcctgccgct tcaaccaggc ctctgcaac caggcgaatt actctcaact ccaccaccgc
901 atgtatggaa actgctatac tttcaatgac aagaacaact ccaacctctg gatgtcttcc

```

```

961 atgctgga tcaacaacg tctgtcctg atgctgogc cagagcagaa tgacttcatt
1021 cccctgctgt ccacagtac tggggcccgg gtaatggtgc acgggcagga tgaacctgcc
1081 tttatggatg atgggtggct taacttgccg cctggcgtgg agacctccat cagcatgagg
1141 aaggaaaccc tggacagact tggggcgat tatggcgact gcaccaagaa tggcagtgat
1201 gttcctgttg agaaccttta ccctcaaaag tacacacagc aggtgtgtat tcaactctgc
1261 ttccaggaga gcatgatcaa ggagtgtggc tgtgcctaca tcttctatcc gcggccccag
1321 aacgtggagt actgtgacta cagaaagcac agttcctggg ggtactgcta ctataagctc
1381 caggttgact tctcctcaga ccacctgggc tgtttcacca agtgccggaa gccatgcagc
1441 gtgaccagct accagctctc tgctggttac tcacgatggc cctcgggtgac atcccaggaa
1501 tgggtcttcc agatgctatc gcgacagaac aattacaccg tcaacaacaa gagaaatgga
1561 gtggccaaaag tcaacatctt cttcaaggag ctgaactaca aaaccaattc tgagtctccc
1621 tctgtcaca tggtcacctt cctgtccaac ctgggcagcg agtgaggcct gtggttcggc
1681 tcctcgggtg tgtctgtggt ggagatggct gagctcgtct ttgacctgct ggtcatcatg
1741 ttccctcatg tgctccgaag gttccgaagc cgatactggt ctccaggccg agggggcagg
1801 ggtgctcagg aggtagctc caccctggca tctcctccctc cttccactt ctgccccac
1861 cccatgtctc tgccttctgc ccagccaggc cctgctccct ctccagcctt gacagccct
1921 cccctgctc atgccacct gggccccgc ccatctccag ggggctctgc aggggccagt
1981 tcctccgctt gtctctggg ggggccctga
/translacion="MEGNKLEEQDSSPPQSTPGLMKGNKREEQGLGPEPAPQOPTAE
EEALIEFHRYSRELFEEFFCNNTTIHGAI RLVC SQHNRMTAFWVWLWLCTFGMMYWF
GLLFGEYFSPVSLNINLNSDKLVFPAVTICTLNPYRYPEIKEELEELDRITEQTLFD
LYKYSSFTTLVAGSRSRDLRGLTLPHPQLRLVPPPHGARRARSVASSLRDNNPQVD
WKDWKIGFQLCNQNKSDCFYQTYSSGVDVREWRHYINILSRLPETLPSLEEDTLG
NFIFACRFNQVSCNQANYSHFHHPMYGNCYTFNDKNNLWMSMPGINNGLSLMLRA
EQNDFIPLLSTVTGARVMVHGQDEPAFMDDGGFNLRPGVETSISMRKETLDRLLGGDYG
DCTKNGSDVPVENLYPSKYTQQVCIHSCFQESMIKECGCAYIFYPQPONVEYCDYRKH
SSWGYYKLVQVDFSSDHLGCFTKCRKPCSVTSYQLSAGYSRWPSVTSQEWVFMQLSR
QNNYTVNNKRNQVAKVNIFFKELNYKTNSESPSVMTVLLSNLGSQWSLWFGSSVLSV
VEMAEVLVDFLLVIMFLMLLRRFRSRYWSPGRGGRGAQEVASTLASSPPSHFCPHMPSL
SLSQPGPAPSPALTAPPPAYATLGRPSPGGSGAGASSACPLGGP"

```

Reference:

AUTHORS Bangel, N., Dahlhoff, C., Sobczak, K., Weber, W.M. and Kusche-Vihrog, K.
TITLE Upregulated expression of ENaC in human CF nasal epithelium
JOURNAL J. Cyst. Fibros. 7 (3), 197-205 (2008)
PUBMED [17766193](http://pubmed.ncbi.nlm.nih.gov/17766193/)

Human ENaC-beta subunit gene 1923 bp, mRNA:

```

1 atgcacgtga agaagtacct gctgaggggc ctgcatcggc tgcagagggg ccccggtacc
61 acgtacaagg agctgctggg gtggactgac gacaacacca acaccacagc ccccaagcgc
121 atcatctgtg aggggcccaa gaagaaagcc atgtggttcc tgctcaccct gctcttcgcc
181 gccctcgtct gctggcagtg gggcatcttc atcaggacct acttgagctg ggaggtcagc
241 gtctccctct ccgtaggctt caagaccatg gacttccccg ccgtcaccaat ctgcaatgct
301 agcccttcca agtattccaa aatcaagcat ttgctgaagg acctggatga gctgatggaa
361 gctgtcctgg agagaatcct ggctcctgag ctaagccatg ccaatgccac caggaacctg
421 aacttctcca tctggaacca cacaccctg gtccttattg atgaacggaa cccccaccac
481 cccatgggtc ttgatctctt tggagacaac cacaatggct taacaagcag ctgagcatca
541 gaaaagatct gtaatgcca cgggtgcaaa atggccatga gactatgtag cctcaacagc
601 acccagtgta ccttccggaa cttaccagc gctaccagg cattgacaga gtggtacatc
661 ctgaggcca ccaacatctt tgcacaggtg ccacagcagg agctagtaga gatgagctac
721 cccggcgagc agatgatcct ggctgccta ttgggagctg agcctgcaa ctaccggaac
781 ttcacgtcca tcttctacc tcaactatggc aactgttaca tcttcaactg gggcatgaca
841 gagaaggcac ttccttcggc caaccctgga actgaattcg gcctgaagt gatcctggac
901 ataggccagg aagactacgt ccccttctc gcgtccacgg ccggggtcag gctgatgctt
961 cagagcaga ggtcataccc cttcatcaga gatgagggca tctacgccat gtcggggaca
1021 gagacgtcca tgggggtact cgtggacaag cttcagcgca tgggggagcc ctacagcccg
1081 tgcaccgtga atgggttctga ggtccccgtc caaaacttct acagtgacta caacacgacc
1141 tactccatcc aggcctgtct tcgctcctgc ttccaagacc acatgatccg taactgcaac
1201 tgtggccact acctgtaccc actgcccctg ggggagaaa actgcaacaa cgggacttc
1261 ccagactggg ccaattgcta ctcagatcta ctgagcagc tggcgagag agagacctgc
1321 attggcatgt gcaaggagtc ctgcaatgac acccagtaca agatgacct ctccatggct
1381 gactggcctt ctgaggcctc cgaggactgg attttccacg tcttgtctca ggagcgggac
1441 caaagcaca atatcacctt gaggcagga ggaattgtca agctcaacat ctacttccaa
1501 gaatttaact atgcaccat tgaagaatca gcagccaata acatcgtctg gctgctctcg
1561 aatctgggtg gccagtttgg cttctggatg gggggctctg tgtgtgctc catcgagttt
1621 ggggagatca tcatcgactt tgtgtggatc accatcatca agctgggtggc cttggccaag
1681 agcctacggc agcggcgagc ccaagccagc tacgctggcc caccgcccac cgtggccgag
1741 ctggtggagg cccacaccaa ctttggcttc cagcctgaca cggccccccg cagccccaac
1801 actgggacct accccagtga gcaggcctg cccatcccag gcaccccgc cccaactat
1861 gactcctgct gctcgcagcc gctggacgct atcgagtctg acagtggagg tgatgcatc
1921 taa

```

```

/translation="MHVKYLLRGLHRLQRGPGYTYKELLVWYCDNTNTHGPKRIICE
GPKKKAMWFLTLFALVWCWQWGFIRTYLSWEVSVLSVGFKTMDFPAVTICNASP
FKYSKIKHLLKDLDELMEAVLERILAPELSHANATRNLNFSIWNHTPLVLIIDERNPHH
PMVLDLFGDNHNGLTSSASEKICNAHGCKMAMRLCSLNRTOCTFRNFTSATQALTEW
YILQATNIFAQVPPQQLVEMSYPGEMILACLFGAEPFNRYNFTSIFYPHYGNICYIFN
WGMTEKALPSANPGTEFGLKILILDIGQEDYVFFLASTAGVRLMLHEQRSYPPFIRDEGI
YAMSGTETSIGVLVDKLRMGEPYSPCTVNGSEVPVQNFYSDYNTTYSIQACLRSFCQ
DHMIRNCNCGHYLYPLPRGEKYCNRRDFPDWAHCYSDLQMSVAQRETCIGMCKESCND
TQYKMTISMADWPSEASEDWIFHVLSQERDQSTNITLSRKGIVKLNIFYQEFNYRTIE
ESAANNIVWLLSNLGGQFGFWMGGSVLCLEFGEI I IDFWVITI IKLVALAKSLRQRR
AQASYAGPPPTVAELVEAHTNFGFQPDTPARSPNTGYPSEQALPIPGTPPPNYDSLRL
LQPLDVIESDSEGDAL"

```

Reference:

AUTHORS Bangel,N., Dahlhoff,C., Sobczak,K., Weber,W.M. and Kusche-Vihrog,K.
TITLE Upregulated expression of ENaC in human CF nasal epithelium
JOURNAL J. Cyst. Fibros. 7 (3), 197-205 (2008)

Human ENaC-gama subunit gene 1950 bp, mRNA:

```

1 atggcaccgc gagagaagat caaagccaaa atcaagaaga atctgcccgt gacgggcccct
61 caggcgccga ccattaaaga gctgatgcgg tggactgcc tcaacaccaa caccatggc
121 tgtcgccgca tctggtgtgc ccgcgccgt ctgcccgcgc tcctctggat cgggttca
181 ctgactccg tggccctcat cctctggcag tgcgcctcc tctcttctc cttctatact
241 gtctcagttt ccaatcaagt ccactccgg aagctggatt ttccctgagc caccatctgc
301 aacatcaacc cctacaagta cagcaccgtt cgccaccttc tagctgactt ggaacaggag
361 accagagagg cctggaagtc cctgatggc tttccagagt cccggaagcg ccgagaggcg
421 gactcctgga actccgtctc agagggaaag cagcctagat tctcccaccg gattccgctg
481 ctgatctttg agacagatga gaagggcaag gccaggggact tcttcacagc gaggaagcgg
541 aaagtccgcg gtagcatcat tcacaaggct tcaaatgtca tgcacatcga gtccaagcaa
601 gtggtgggat tccaactgtg ctcaaatgac acctccgact gtgccacctc caccttcagc
661 tcgggaatca atgccattca ggagtggat aagctacact acatgaacat catggcacag
721 gtgcctctgg agaagaaaat caacatgagc tattctgctg aggagctgct ggtgacctgc
781 ttctttgatg gactgtctct gtagtccagg aatttcacgc ttttccacca cccgatgcat
841 gggaaattgct atactttcaa caacagagaa aatgagacca ttctcagcac ctccatgggg
901 ggcagcgaat atgggctgca agtcatcttg tacataaagc aagaggaata caacccttc
961 ctgctgtctc ccaactggagc taaggtgac atccatcggc aggatgagta tccctctctc
1021 gaagatgtgg gaacagagat tgagacagca atgggtcacct ctataggaat gcacctgaca
1081 gactccttca agctgagatga gcctacagt cagtgcacgg aggaaggagg tgactgcca
1141 atcaggaaca tctacaacgc tgcctactcg ctccagatct gccttcattc atgcttccag
1201 acaagatggg tggagaaaat tgggtgtgcc cagtacagcc agcctctacc tctgcagcc
1261 aactactgca actaccagca gcaccccaac tggatgtatt gttactacca actgcatcga
1321 gcctttgtcc aggaagagct gggctgcccag tctgtgtgca aggaagcctg cagctttaa
1381 gactggacac taaccacaag cctggcaca tggccatctg tggtttcgga gaagtgggtg
1441 ctgctgtctc ccaactggagc caagggcgg caagtaaaaca aaaagctcaa caagacagac
1501 ttggccaaac tcttgatatt ctacaaagc ctgaaccaga gatccatcat ggagagccca
1561 gccaacagta ttgagatgct tctgtccaac ttcggtggcc agctgggctc gtggatgagc
1621 tgctctgttg tctgcgtcat cgagatcatc gaggtcttct tcattgactt cttctctatc
1681 attgccgcc ccagtgagca gaaagccaag gactgtgtgg cctggaaaca ggctcccca
1741 tgtccagaag ctccccgtag cccacagggc caggacaatc cagccctgga tatagacgat
1801 gacctacca ctttcaactc tgccttgcac ctgcctccag ccctaggaac ccaagtgcc
1861 ggcacaccgc cccccaaata caatacctg cgcttggaga gggccttttc caaccagctc
1921 acagatacc agatgctgga tgactctga

```

```

/translation="MAPGEKIKAKIKKNLPVTGPQAPTIKELMRWYCLNTHGCRRI
VVSRRGLRLLWIGFTLTAVALILWQCALLVFSFYTVSVSIKVHFRKLDFFPAVTICNI
NPYKYSTVRHLLADLEQETREALKSLYGFPESRKRREAESWNSVSEKQPRFVSHRIP
LIFDQDEKGRDFFTGRRKRVGSGIIHKASVMHIESKQVVGFLCSNDTSDCATYT
FSSGINAIQEWYKLHYMNIMAQVPLEKKINMSYSABELLVTCFFDGVSCDARNFTLFH
HPMHGNCYTFNNRENETILSTSMGGSEYGLQVILYINEEYNPFLVSSTGAKVIIHQ
DEYPFVEDVGTETETAMVTSIGMHLTESFKLSEYSCQTEDGSDVPIRNIYNAAYSLQ
ICLHSCFQTKMVEKCGCAQYSQPLPPAANYCNYQQHPNWMYCYQLHRAFVQEEELGCQ
SVCKEACSFKEWTLTSLAQWPSVSEKLLPVLTDWQGRQVKNKLNKTDLAKLLIFY
KDLNQRSIMESPANSIEMLLSNFGGQLGLWMSCSVVCVIEIEIEVFFIDFFSIIARRQW
QKAKEWAWKQAPPCEAPRSPQGQDNPALDIDDDLPFTNSALHLLPALGTQVPGTTP
PKYNTLRLERAFSNQLTDTQMLDEL"

```

Reference:

AUTHORS Bangel,N., Dahlhoff,C., Sobczak,K., Weber,W.M. and Kusche-Vihrog,K.
TITLE Upregulated expression of ENaC in human CF nasal epithelium
JOURNAL J. Cyst. Fibros. 7 (3), 197-205 (2008)

7. Discussion

In animal kidney, ENaC plays a crucial role in controlling sodium reabsorption to keep the normal blood pressure. It was reported that the expression of ENaC mRNA in the kidney of Dahl salt-sensitive (DS) rats was abnormally regulated by aldosterone. The expression of α -ENaC mRNA in DS rats was abnormally increased by high sodium diet in contrast to Dahl salt-resistant (DR) rats, while it was normally increased by low sodium diet in DS rats similar to DR rats. The expression of beta- and gamma-ENaC mRNA in DS rats was also abnormally increased by high sodium diet unlike DR rats. The expression of serum and glucocorticoid-regulated kinase 1 (SGK1) mRNA was elevated by high sodium diet in DS rats, but it was decreased in DR rats. The expression of ENaC and SGK1 mRNA is abnormally regulated by dietary sodium in salt-sensitively hypertensive rats, and that this abnormal expression would be one of the factors causing salt-sensitive hypertension (Aoi et al., 2007).

Correspondence to:

Hongbao Ma, PhD
Bioengineering Department
Zhengzhou University
Zhengzhou, Henan 450001, China
ma8080@gmail.com
01186-137-8342-5354

Brookdale University Hospital and Medical Center
New York 11212, USA,
ma8080@gmail.com
347-321-7172

References

1. Aoi W, Niisato N, Sawabe Y, Miyazaki H, Tokuda S, Nishio K, Yoshikawa T, Marunaka Y. 2007. Abnormal expression of ENaC and SGK1 mRNA induced by dietary sodium in Dahl salt-sensitively hypertensive rats. *Cell Biol Int* 31(10):1288-1291.
2. Butterworth MB, Edinger RS, Frizzell RA, Johnson JP. 2009. Regulation of the epithelial

- sodium channel by membrane trafficking. *Am J Physiol Renal Physiol* 296(1):F10-24.
3. Gormley K, Dong Y, Sagnella GA. 2003. Regulation of the epithelial sodium channel by accessory proteins. *Biochem J* 371(Pt 1):1-14.
4. Hummler E. 2003. Epithelial sodium channel, salt intake, and hypertension. *Curr Hypertens Rep* 5(1):11-18.
5. Loffing J, Korbmayer C. 2009. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). *Pflugers Arch* 458(1):111-135.
6. Ma HP, Chou CF, Wei SP, Eaton DC. 2007. Regulation of the epithelial sodium channel by phosphatidylinositides: experiments, implications, and speculations. *Pflugers Arch* 455(1):169-180.
7. Nielsen J, Kwon TH, Christensen BM, Frokiaer J, Nielsen S. 2008. Dysregulation of renal aquaporins and epithelial sodium channel in lithium-induced nephrogenic diabetes insipidus. *Semin Nephrol* 28(3):227-244.
8. Pochynyuk O, Bugaj V, Stockand JD. 2008. Physiologic regulation of the epithelial sodium channel by phosphatidylinositides. *Curr Opin Nephrol Hypertens* 17(5):533-540.
9. Sagnella GA, Swift PA. 2006. The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressure. *Curr Pharm Des* 12(18):2221-2234.
10. Swift PA, MacGregor GA. 2004. The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. *Am J Pharmacogenomics* 4(3):161-168.
11. Teiwes J, Toto RD. 2007. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. *Am J Hypertens* 20(1):109-117.

6/5/2009